Contact Information
WenYong Chen, Ph.D.
  • Associate Professor, Cancer Biology


Professional Experience

  • 2012–present Associate Professor, Department of Cancer Biology, Beckman Research Institute, City of Hope, Duarte, California
  • 2005–present Full member, Comprehensive Cancer Center of City of Hope, Duarte, California
  • 2005–present Faculty, City of Hope Graduate School, Duarte, California
  • 2005 – 2011 Assistant Professor, Division of Biology, Beckman Research Institute, City of Hope, Duarte, California
  • 2000 – 2005 Postdoctoral Fellow, Cancer Biology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 
  • 1993 – 1999 Graduate Program of Cellular and Molecular Biology, and Graduate Research Assistant in Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham.


  • 2005   Postdoc     Cancer Biology           Johns Hopkins University
  • 1999   Ph.D.         Molecular Biology       University of Alabama at Birmingham
  • 1988   M.S.           Biochemistry              Shanghai Second Medical University /  Shanghai Institute of Biological Products, China
  • 1985  B.S.             Chemistry                  Zhejiang University, China


  • 2013    Lymphoma Research Award, Tim Nesvig Lymphoma Research Fund
  • 2013    COH-UCR Biomedical Research Initiative Award, City of Hope-University of California Riverside
  • 2008    Research Scholar Award, American Cancer Society
  • 2007    Translational Cancer Research Award, The V-foundation, Cary, NC
  • 2006    Research Career Development Award, STOPCANCER foundation, Los Angeles, CA
  • 2005    Hypothesis Development Award, US Department of Defense CML Program
  • 2005    The A. McGehee Harvey Award for Outstanding Postdoctoral Research Contributions, The Young Investigators’ Day, Johns Hopkins University School of Medicine
  • 2004    “Scholar-In-Training Award” for postdoctoral fellows, American Association of Cancer Research
  • 1999    The John R. Durant Award for Excellence in Cancer Research for Postdoctoral Fellow, Comprehensive Cancer Center, University of Alabama at Birmingham
  • 1999    Postdoctoral Research Fellowship, Cooley's Anemia Foundation, New York
  • 1998   The Jack M. McKibbin Pre-doctoral Research Fellow Award Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham
  • 1998    The John R. Durant Award for Excellence in Cancer Research for Graduate Students                                                        Comprehensive Cancer Center, University of Alabama at Birmingham
  • 1996     A Merit-based Travel Award from American Society of Hematology for its 38th Annual Meeting in Orlando, Florida


  • Roth, M. and Chen W.Y.  Sorting out functions of sirtuins in cancer.  Oncogene.  doi:10.1038/onc.2013.120.  2013
  • Yuan, H. Su, L. and Chen, W.Y. The emerging and diverse roles of sirtuins in cancer: A clinical perspective.  Oncotarget & Therapy  6:1399-1416, 2013.
  • Wang, Z. and Chen, W.Y. Emerging roles of SIRT1 in cancer drug resistance. Genes & Cancer.  4: 82-90, 2013.
  • Chen, W.Y. and Bhatia, R.  Roles of SIRT1 in leukemogenesis. Curr Opin Hematol  20: 308-313, 2013.
  • Wang, Z., Yuan, H., Roth M., Stark, J., Bhatia, R., and Chen, W.Y.  SIRT1 promotes error-prone DNA damage repair and acquisition of genetic mutations in CML cells. Oncogene 32: 589-598, 2013.
  • Chen, W.Y.  Cancer Acquired Resistance: A New Lesson from Chronic Myelogenous Leukemia. J Bone Marrow Res 1: e101, 2013.
  • Chen, W.Y. Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance. Oncotarget 3: 363-364,  2012.
  • Li, L., Wang, L., Li, L., McDonald, T., Ho, Y., Holyoake T., Chen, W.Y.# and Bhatia, R.#   Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with Imatinib. Cancer Cell 21: 266-281, 2012. #Co-corresponding authors.
  • Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Stark, J., Bhatia, R.#, and Chen, W.Y.#  Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.  Blood 119: 1904-1914, 2012. #Co-corresponding authors. 
  • Yuan, H., Wang, Z ., Zhang, H., Bhatia, R. and Chen, W.Y. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.  Carcinogenesis 33: 285-293, 2012
  • Chakraborty, S., Stark, J.M., Sun,C.L., Modi, H., Chen, W.Y., O’Connor T., Forman, S.J., Bhatia, S., and Bhatia R.  Chronic Myelogenous Leukemia Stem and Progenitor Cells Demonstrate Chromosomal Instability Related to Repeated Breakage-Fusion-Bridge Cycles Mediated by Non-Homologous End Joining. Blood 119: 6187-6197, 2012.
  • Nam S., Scuto A., Yang F., Chen W.Y., Park S., Yoo H.S., Konig H., Bhatia R., Cheng X., Merz K.H., Eisenbrand G., and Jove R.  Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of STAT5 signaling.  Molecular Oncology  6: 276-283, 2012.
  • Chen, W.Y., Yuan, H. and Wang, Z.  De novo acquisition of BCR-ABL mutations for CML acquired resistance. In Myeloid Leukemia: Basic Mechanisms of Leukemogenesis. Steffen Koschmieder and Utz Krug (eds). pp 69-84.  INTECH.  2011. (Open access)
  • Wang, B., Hasan, K.M., Alvarado, E., Yuan, H., Wu, H. and Chen, W.Y. NAMPT over-expression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30: 907-921, 2011.
  • Yuan, H., Wang ,Z., Gao, C., Chen, W., Huang, Q., Yee, J.K., Bhatia, R., and Chen, W.Y. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J. Biol. Chem. 285: 5085-5096, 2010.
  • Chen, W.Y., Wang, D.H., Chiu, R.W., Lou, J.Y., Gu, W. and Baylin, S.B. Tumor suppressor HIC1 directly regulates SIRT1 deacetylase to modulate p53-dependent apoptotic DNA damage responses. Cell 123: 437-448, 2005.
  • Chen, W.Y., Cooper, T.K., Zahnow, C.A., Overholtzer, M., Zhao, Z., Ladanyi, M., Karp, J.E., Gokgoz, N., Wunder, J.S., Rulis I.L., Levine A.J., Mankowski J.L., and Baylin S.B. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6: 387-398, 2004.
  • Chen, W.Y., Zeng, X., Carter, M.G., Morrell, C.N., Chiu Yen, R.W., Esteller, M., Watkins, D.N., Herman, J.G., Mankowski, J.L., and Baylin, S.B. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat. Genet. 33: 197-202, 2003.
  • Chen W.Y. & Townes T.M.  Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc Natl Acad Sci U S A, 97: 377-382, 2000.
  • Chen W.Y., Wu X., Levasseur D.N., Liu H., Lai L., Kappes J.C. & Townes T.M.  Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice. Stem Cells, 18, 352-359, 2000.
  • Chen W.Y., Bailey E.C., McCune S.L., Dong J.Y. & Townes T.M. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A, 94: 5798-5803, 1997.


For more information on Dr. Chen's research, please click here.